Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastian Bauer

Showing results (361-370 of 408) with videos related to

Pageof 41
Sort By:
Oncotarget|October 7, 2015
Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathwayRajmohan Murali, Raghu Chandramohan, Inga Möller, et al.
JTCVS Open|December 31, 2025
Outcome of patients with curative-intent treatment for primary pulmonary sarcoma: Results from an international multicenter retrospective studyStephane Collaud, Theresa Stork, Dagmar Adamkova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2025
Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUEMichael C Heinrich, Jean-Yves Blay, Hans Gelderblom, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 18, 2023
MicroRNA-335-5p suppresses voltage-gated sodium channel expression and may be a target for seizure controlMona Heiland, Niamh M C Connolly, Omar Mamad, et al.
Iscience|December 9, 2025
Sorafenib as first-line therapy for metastatic uveal melanoma: A multicenter, placebo-controlled randomized discontinuation study (STREAM)Halime Kalkavan, Max E Scheulen, Eckhart Kämpgen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2021
Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute LeukemiaEytan M Stein, Daniel J DeAngelo, Jörg Chromik, et al.
Annals of Surgical Oncology|June 14, 2013
Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experiencePiotr Rutkowski, Alessandro Gronchi, Peter Hohenberger, et al.
Lancet (London, England)|November 27, 2012
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trialGeorge D Demetri, Peter Reichardt, Yoon-Koo Kang, et al.
Genes, Chromosomes & Cancer|June 6, 2020
Germline SDHB-inactivating mutation in gastric spindle cell sarcomaChristoph E Heilig, Peter Horak, Daniel B Lipka, et al.
Lancet (London, England)|June 24, 2019
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trialWilliam D Tap, Hans Gelderblom, Emanuela Palmerini, et al.
Pageof 41

Showing results (361-370 of 408) with videos related to

Sort By:
Pageof 41
Oncotarget|October 7, 2015
Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathwayRajmohan Murali, Raghu Chandramohan, Inga Möller, et al.
JTCVS Open|December 31, 2025
Outcome of patients with curative-intent treatment for primary pulmonary sarcoma: Results from an international multicenter retrospective studyStephane Collaud, Theresa Stork, Dagmar Adamkova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2025
Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUEMichael C Heinrich, Jean-Yves Blay, Hans Gelderblom, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 18, 2023
MicroRNA-335-5p suppresses voltage-gated sodium channel expression and may be a target for seizure controlMona Heiland, Niamh M C Connolly, Omar Mamad, et al.
Iscience|December 9, 2025
Sorafenib as first-line therapy for metastatic uveal melanoma: A multicenter, placebo-controlled randomized discontinuation study (STREAM)Halime Kalkavan, Max E Scheulen, Eckhart Kämpgen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2021
Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute LeukemiaEytan M Stein, Daniel J DeAngelo, Jörg Chromik, et al.
Annals of Surgical Oncology|June 14, 2013
Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experiencePiotr Rutkowski, Alessandro Gronchi, Peter Hohenberger, et al.
Lancet (London, England)|November 27, 2012
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trialGeorge D Demetri, Peter Reichardt, Yoon-Koo Kang, et al.
Genes, Chromosomes & Cancer|June 6, 2020
Germline SDHB-inactivating mutation in gastric spindle cell sarcomaChristoph E Heilig, Peter Horak, Daniel B Lipka, et al.
Lancet (London, England)|June 24, 2019
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trialWilliam D Tap, Hans Gelderblom, Emanuela Palmerini, et al.
Pageof 41